Event RAKERNAS PABMI XIV
Improving the professional Existence of Oral and Maxillofacial Surgeons through advanced skill and knowledge
AANHS Event April 2019
AANHS - ASIAN AUSTRALIAN NEURO & HEALTH SCIENCE INTERNATIONAL CONFRENCE
Events held at Grand Aston City Hall & University of Sumatra Utara Hospital Medan
Welcoming the best Spine Treatment for the New Generation!
National Medical Group (IRENE) in Arab Health 2017
| Welcome to visit us at Arab Health 2017 |
| Naton Medical Group will attend Arab Health 2017.
Welcome to visit us at S1A59!
|
Unique Double Award for Ulrich Medical
In an exceptional collaborative project, a team of trainees from ulrich medical and students from the South Württemberg Student Research Center developed an innovative solution to reduce wear of the milling cutter during machining.
Following initial difficulties, the breakthrough was achieved using a special measurement set-up developed by the project team. "It is extremely rare for patentable technology to result from collaboration of this kind. Yet in this case, we were fortunate and we have submitted it for a patent," Klaus Kiesel, CEO of ulrich medical, was pleased to report. "We are convinced that with the newly developed method, we can optimize not only our own production processes but also other industries can benefit from it."
The new real-time control reduces tool wear by more than 80 percent and decreases consumption of the expensive raw material hard metal which is very energy-intensive to produce. In addition, there is a reduction in manufacturing time which can vary per implant, depending on wear of the milling cutter.
It was not just the jury of the 2016 "Jugend forscht" (Young Researchers) state competition who was impressed by these results. The young researchers were able to reach second place straightaway in the working world specialist field with their project.
ulrich medical was now honored as one of the "100 Companies for Resource Efficiency" and "100 Sites for Industry 4.0" in two more competitions. Both programs were initiated by the state government of Baden-Württemberg.
The initiative "100 Companies for Resource Efficiency" was launched as part of the state strategy for resource efficiency by the Ministry of the Environment of Baden-Württemberg and industry representatives. In addition to energy efficiency, the objective with regard to the topic of resource efficiency in the industry was to once again increase the focus on material efficiency in particular. The collaborative project achieved both objectives. Environment minister Franz Untersteller presented the award in October in Karlsruhe.
With the competition “100 Sites for Industry 4.0 in Baden-Württemberg,” the state of Baden-Württemberg honored innovative concepts from the economy which were successful at intelligently networking production and value-creation processes. In addition to the degree of innovation, the jury of experts also assessed the specific practical relevance for industry 4.0. On November 7, the prize was awarded by the minister of economic affairs Nicole Hoffmeister-Kraut in Stuttgart.
"We are proud to be the only company with its project honored in both future-minded initiatives," says Christoph Ulrich, managing partner of ulrich medical. "Little by little, the procedure developed is now being implemented in all of our production machines. In the medium term, the system is intended to be further developed in such a way that it can be used by all machining centers as well as by other industries."
Fascination with medical technology
ulrich medical develops, produces and markets innovative medical technology. Physicians and users worldwide trust our more than 100 years of experience. With product divisions in spinal implants, contrast media injectors, foot surgery as well as surgical instruments and tourniquets, ulrich medical offers a comprehensive portfolio of innovative products. As one of the few in the industry with development and production in Germany, the medical technology company from Ulm places great value on "Made in Germany".
Immedicom in EFORT Congress 2016
Event : EFORT congress 2016
Period : June 1st(Wed) ~ 3rd(Fri) 2016
Location : PALEXPO, Switzerland
EFFORT congress 2016 was held from June 1st ~ 3rd at PALEXPO. This year is the 167h EPORT congress. About 7,000 person attend this congress every year and it is also held in different European areas every year. We introduced our new product Battery powered system, Video guided catheter, kyphoplasty system and orthopedic medical products and had meeting with many distributors. IMEDICOM CO., LTD. will try to do best to enter the world market by attending main congress and exhibitions.
Cantel Medical Expands its Direct Sales Operations in Canada through the Acquisition of its Endoscopy Assets from Vantage Endoscopy
LITTLE FALLS, N.J., Sept. 26, 2016 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE: CMN), a leading global company dedicated to delivering innovative infection prevention products and services, today announced that the Company has expanded its direct sales operations in Canada by acquiring endoscope reprocessing business assets from its Canadian distributor, Vantage Endoscopy, Inc., a subsidiary of Diploma Canada Holdings Ltd. The endoscope reprocessing business consists of Cantel's Medivators®-branded automated endoscope reprocessors, chemistries, consumables and a full sales and service organization.
Jorgen B. Hansen, President and CEO of Cantel Medical said, "This acquisition is consistent with Cantel's strategy to expand its products and services into key markets to provide global solutions that meet local needs. We are pleased to be able to offer customers an expanded Medivators®-branded product portfolio while providing the same level of high-quality service and support they have always received. We look forward to continuing these relationships and partnering with them in the future."
"The expansion of our commercial platform and the addition of a direct sales and service organization for our Endoscopy business will further strengthen Cantel's share in the infection prevention market in Canada." stated Michael Spicer, President, Americas Sales, UK, Canada, Latin America and Global Service. "Expanding our presence in the Canadian market will enable us to realize the full potential of our portfolio while also enabling us to offer a broader suite of infection prevention products from all Cantel divisions."
Ex-Duke football player: How I had my heart attack (and what you can learn from it)
Heart disease is the number one cause of death for both men and women in the United States. Claiming approximately 1 million lives per year, heart attacks alone strike someone every 43 seconds. On January 20, 2014, that someone was me.
That day in January began typically enough with a trip to the gym. I have always been physically active – I played football at Duke University – and I know how exercise benefits the body and the mind. What was not typical however, was the incredible pressure I felt in my chest after twenty minutes on the elliptical machine. I tried to ignore it and hoped it would go away, but when the pressure turned to pain, I knew something was wrong.
When I got home from the gym, I called 9-1-1. I felt cold and clammy, and I was certain I was having some sort of heart event. At the hospital, medical professionals confirmed I was having a heart attack, and I was rushed to the catheter lab to clear any blockages in my arteries. The doctors performed a coronary angioplasty to relieve the blockages, restore blood flow and ease the pressure on my heart.
For me, heart disease is very personal; my father was a heart patient, and – like father, like son – now I was as well. Statistically, that is not that surprising. Black Americans are at a greater risk for cardiovascular disease than white Americans, and black men between the ages of 45 and 64 have a 70 percent higher risk of developing heart failure than white men.
On the way to the catheter lab, lying helpless on the hospital bed, I thought about my father who had quadruple heart bypass surgery years ago.
On the way to the catheter lab, lying helpless on the hospital bed, I thought about my father who had quadruple heart bypass surgery years ago. His surgery was successful, but the recovery period was difficult and lengthy, and it put great a strain on him and on our family. I feared this same scenario would come to pass for me and my family too. Happily for me that was not the case. After only two days in the hospital I returned home feeling better than I had in months.
Heart attack treatment has come a long way. According to the Society for Cardiovascular Angiography and Interventions, a patient who suffered a heart attack in the 1950s was typically treated with weeks of bed rest and pain medications. Survival rates were low. Now, approximately 96 of every 100 heart attack patients who receive treatment not only survive, but are usually released from the hospital and back to work within a week.
A number of innovations have made this dramatic progress possible. Angioplasty is one of these key innovations. In my father’s case, open-heart bypass surgery (CABG) was the only way doctors could restore blood flow to the heart. But advances in technology have led to less invasive approaches. In my case, only a small incision was required to insert the catheter that opened the artery with a balloon-like mechanism and insert the stent to hold the artery open.
Innovative medical technology not only saved my life; it was also the key factor contributing to my speedy recovery. My father was my hero and someone I tried to emulate in many ways, but in this case, it meant I did not have to follow in my father’s footsteps.
Director of Global Marketing Solutions & Support at Marriott International, and a former stand-out Duke football player. He currently resides in Gaithersburg, Maryland, with his wife and two children
Cohera Medical, Inc.® Receives FDA Approval to Begin Clinical Trials of its Sylys® Surgical Sealant in the U.S.
Breakthrough Surgical Sealant Designed to Help Reduce Anastomotic Leaks for Patients Undergoing Colorectal Surgery
RALEIGH, N.C., July 12, 2016 (GLOBE NEWSWIRE) -- Cohera Medical, Inc., a leading innovator and developer of absorbable surgical adhesives and sealants, today announced that it has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration (FDA) to begin a prospective, multicenter, randomized clinical trial for its Sylys® Surgical Sealant device.
/EIN News/ -- Sylys® Surgical Sealant is intended to be used as an adjunct to standard closure techniques for the reinforcement and protection of anastomotic junctions in colorectal and ileorectal anastomosis procedures. Sylys is a resorbable synthetic sealant designed to help reduce anastomotic leakage by providing additional support to the anastomosis during the first few days of healing, when the development of leaks is most likely to occur.
“It is tremendous that the FDA has given investigational approval to this novel device that may help reduce the incidence of anastomotic leaks and their devastating impact,” said Dr. Deborah Nagle, Chief, Colon and Rectal Surgery, Beth Israel Deaconess Medical Center in Boston, MA. Sylys® Surgical Sealant received Expedited Access Pathway (EAP) status from the FDA in 2015, which recognizes the potential of the product to meet a serious unmet clinical need. This IDE approval represents the culmination of significant joint efforts by the company and the FDA to move forward on the clinical evaluation of this important technology.
“Anastomotic leakage is the most devastating complication associated with intestinal resection, contributing to morbidity and mortality,” said James McCormick, DO, FACS, FASCRS, Program Director, General Surgery, Allegheny Health Network in Pittsburgh, PA. “We have made tremendous strides in curtailing the risk associated with intestinal anastomosis, but we are always striving for further improvement and greater patient safety.”
The randomized clinical study will compare patients undergoing colorectal and ileorectal anastomosis after resection with and without the sealant. The study is the first phase of a clinical trial program designed to support the safety and efficacy of the sealant in reducing the leak rate in these procedures.
Anastomotic leakage, which occurs in up to 23 percent of patients undergoing colorectal surgery, is considered to be the most serious surgical complication encountered, frequently resulting in the rapid development of severe peritonitis, septic shock, multiple organ dysfunction, and death. At least one third of post-surgical deaths following colorectal surgery are attributed to leaks, and survivors generally have protracted and expensive recoveries.
“We are pleased that the FDA has approved this IDE. This approval validates the Sylys® Surgical Sealant biocompatibility, pre-clinical safety profile, and clinical trial design of the study,” said Chad Coberly, JD, Chief Clinical and Legal Officer of Cohera. “The Company greatly appreciates the cooperation and high level of interaction with the FDA during the review of this potentially life-saving healthcare innovation.”
The market for Sylys® Surgical Sealant is significant, with more than one million procedures per year worldwide representing a multi-billion dollar opportunity. Due to the unmet clinical need, Sylys would represent a breakthrough in this market that will lead to improved patient outcomes as well as reduced patient management costs for healthcare providers.